Diclazepam

Diclazepam (also known as chlorodiazepam or 2'-chloro-diazepam) is a long-acting benzodiazepine first synthesized by Leo Sternbach at Roche in the 1960s but never developed into a pharmaceutical product. It is structurally related to diazepam, differing by the addition of a chlorine atom at the 2'-position of the phenyl ring. Like diazepam, it produces broad-spectrum benzodiazepine effects — anxiolysis, sedation, muscle relaxation, and anticonvulsant activity — but with a substantially longer duration of action and a complex metabolic profile that includes the production of active metabolites, notably delorazepam, that significantly extend its pharmacological duration.

Diclazepam entered the research chemical market in the early 2010s and has been used recreationally and by those seeking to manage withdrawal from other benzodiazepines or GABAergic substances. Community experience on Reddit includes at least six posts discussing its use, with accounts ranging from self-managed detoxification from tianeptine and opioids to recreational use for anxiety. The very long half-life of diclazepam — estimated at 42+ hours, with active metabolites extending activity further — makes it particularly problematic for recreational use: cumulative accumulation with repeated dosing can produce profound sedation days after use, making dose titration genuinely dangerous.

Diclazepam has no established medical use, approved therapeutic dosing, or clinical safety data in humans. Its use carries all the risks of pharmaceutical benzodiazepines plus additional hazards from incomplete pharmacological characterization.